Merck, Inc.
A Study of MK-2060 in Healthy Participants (MK-2060-016)
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT06582602
- Locations
- 🇺🇸
Advanced Pharma CR, LLC ( Site 0002), Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0001), Knoxville, Tennessee, United States
A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06580587
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06575959
- Locations
- 🇺🇸
Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
🇺🇸The Texas Liver Institute ( Site 0001), San Antonio, Texas, United States
A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06575933
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06575595
- Locations
- 🇺🇸
QPS Missouri ( Site 0003), Springfield, Missouri, United States
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06566989
- Locations
- 🇬🇧
Quotient Sciences ( Site 0001), Nottingham, Nottinghamshire, United Kingdom
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06567002
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase ( Site 0001), South Miami, Florida, United States
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06554639
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
MSD Belzutifan PAS
- Conditions
- Von Hippel Lindau Disease
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06554730
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
- Conditions
- Classical Hodgkin Lymphoma RecurrentPrimary Mediastinal Large B-cell Lymphoma RecurrentClassical Hodgkin Lymphoma RefractoryPrimary Mediastinal Large B-cell Lymphoma Refractory
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06504394
- Locations
- 🇵🇱
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 0501), Warszawa, Mazowieckie, Poland
🇺🇸Clinical Research Alliance ( Site 0101), Westbury, New York, United States
🇦🇺Westmead Hospital ( Site 0901), Westmead, New South Wales, Australia